Life Sciences Innovation Export Hub will host its first Bootcamp on 25 November 2020 via Zoom
Please join us for the Life Sciences Innovation Export Hub’s introductory virtual bootcamp – a new collaboration in life sciences between Life Sciences Queensland, Australia China Technology Incubator and Queensland University of Technology supported by the DISER’s SME Export Hub Program to offer SMEs, startups, entrepenerurs and researchers in the life sciences sector insight and access to Asian export markets.
This will be our first event for Hub participants and provide participants exclusive access to a number of industry and sectoral leaders such as Brandwood CKC, FB Rice, H+ Labs/TUS, MTPConnect and more.
Topics to be discussed include:
- key Asian markets
- regulatory pathways
- IP considerations
- the state of both life sciences and health sectors in Australia and Asia Pacific
- case studies from SMEs and organisations who are currently navigating the pathway to commercialisation and export in Asia Pacific
Who can attend?
Please note that numbers for this half-day virtual bootcamp, will be kept limited to ensure an interactive event, with opportunities for participants to interact directly with speakers and the Hub partners to answer queries and provide guidance. As such, registration to this event is a competitive selection process with limited availability so to ensure your attendance at the virtual Bootcamp please apply for the program by Wednesday 18 November.
Successful selection into the Bootcamp will also secure you access to the Hub’s online module component and exclusive opportunities to progress through the Hub Program phases to Asian immersion and residency opportunities.
Grant Bennett: Brandwood CKC
Grant Bennett has a deep and practical experience of regulatory affairs gained through medical devices industry roles across the Asia Pacific. His prior experience includes roles as Regional Regulatory Affairs Manager Asia Pacific and Australia/New Zealand Quality Assurance Manager with a US-headquartered, multinational supplier of professional Medical Devices.
An internationally respected industry leader, Grant chairs both the Regulatory Affairs Expert Panel and National Advisory Council for Australian industry peak body AusMedtech. He is an adviser to the Asian Harmonization Working Party (AHWP), supporting regulatory guidance development in pre-market assessments, labelling and UDI implementation.
Grant has specialist expertise in distribution and logistics and requirements for Universal Device Identifiers (UDI) and national implementations including the Australian National Product Catalogue (NPC) controlled by the Australian National E-Health Transition Authority and the corresponding DHB National Catalogue for Healthcare in New Zealand.
Wesa Chau: Cultural Intelligence
An influential entrepreneur and social innovator, Wesa is a thought leader on cultural diversity and leadership, and has held several senior managerial and governance positions. Wesa is currently CEO of Cultural Intelligence and an advisory board member of the National Foundation of Australia-China Relations.
Wesa was one of the key authors of a number of ground-breaking research alongside Emeritus Professor John Fitzgerald, including the Asian-Australian Diaspora in Philanthropy research commissioned by the Lord Mayor Charitable Foundation and International Cultural Engagements among Australians of Pacific Islands and Asian Descent commissioned by Australia Council of Learned Academies. She was awarded the inaugural Swinburne-Scanlon Intercultural Fellowship to Malaysia and India supported by the Department of Foreign Affairs and Trade (DFAT) to better understand how other countries manage cultural diversity.
She was a co-founder of Resilience Against Racism to support multicultural communities, in particular Asian-Australians and contributes to social cohesion and harmony in Australia. Wesa was named as the 2020 40 under 40 Most Influential Asian-Austrailans (education category winner), and inductee to the Victorian Honour Roll of Women 2012 for her commitment to gender equality, cultural diversity and social cohesion.
Wesa is currently undertaking her PhD at Swinburne University understanding what political skills are and how people develop them. She holds a Masters in Business Management, Graduate Diploma in Law and Bachelors of Engineering and Commerce with majors in software engineering and marketing. Wesa is also a graduate of the Australian Institute of Company Directors and it’s a qualified teacher.
Declan McKeveney: FB Rice
Declan is a Senior Counsel in the FB Rice chemistry team. He has a PhD in chemistry and research experience in the fields of organic, biological and medicinal chemistry and pharmacology. Declan practices in all areas of chemistry, with a focus on pharmaceutical compounds and drug technologies.
Declan assists clients with the construction and ongoing management of local and international patent portfolios with an eye to adding value to his client’s businesses and ensuring alignment of their intellectual property (IP) strategy with the broader business objectives. Declan therefore spends a lot of his time preparing and filing new patent applications for local clients and managing the prosecution of the ensuing portfolio in key international jurisdictions including the U.S., Europe, China, and Japan, as well as Australia. His clients also benefit from advice around protection strategies, freedom to operate and validity issues.
Lara Gun: FB Fice
Lara is a Senior Associate in the FB Rice trade marks team and is a registered Australian and New Zealand Trade Marks Attorney and trade marks lawyer. Lara commenced her IP career as a trade mark filing clerk, trade mark lodgements officer and trade mark searcher at a national Australian IP firm. After completing her Bachelor of Law at the University of Technology, Sydney, she worked with two of Australia’s top tier law firms as a trade marks lawyer and attorney.
Lara’s particular strength is delivering timely, commercially focused and pragmatic advice, not only for protection of trade marks and brands, but the effective enforcement and exploitation of rights. Lara has a keen interest in the craft food and beverage sectors as well as clean green products such as industrial hemp and is an active member of a number of key organisations in these fields.
Lara contributes to the firm’s pro bono program for not-for-profit and charitable organisations and is part of our trade marks group ranked Tier 1 for trade mark prosecution by Managing Intellectual Property’s IP Stars survey.
Carl Hinze: Holding Redlich
Carl Hinze is a Partner and Head of China Practice at national law firm, Holding Redlich. Before joining Holding Redlich in 2014, Carl worked in law and investment banking in Shanghai for 10 years. Before becoming a cross-border corporate and dispute resolution lawyer, Carl lectured at the University of Queensland in the School of Languages and Cultures.
Carl completed his PhD in Chinese Studies as well as a Bachelor of Arts (Hons) and a Bachelor of Laws at the University of Queensland. Carl’s PhD thesis examined the universal and culture-specific aspects of the Chinese concept of ‘face’. He is a recognised expert in the field of Chinese sociolinguistics and politeness research.
Carl has been a grateful recipient of three scholarships to China offered by the Australia-China Council and he previously served as a Project Officer for the Australia-China Council’s Australian Studies in China Program.
Carl’s legal practice focuses on cross-border investment, including China and US-related mergers and acquisitions. He has also represented multinational clients in complex arbitration proceedings involving protracted disputes between business partners in China and other parts of Asia.
Carl met his wife at UQ and their wedding ceremony was held on campus in 2007.
Anthony Cole: H+Labs
H+Lab is a strategic partner with the Australia China Technology Incubator, providing commercialisation advice and support to Business & Government. H+Lab and ACTI are supporting the QUT/ LSQ SME Export Hub program in the SE Asia market.
Since first venturing to China in 2007, Anthony has been involved in Export, Tourism, Health, Clean Energy, Investment & Education business with China, establishing a company in China (Qingdao) in 2015.
In 2017 Anthony brokered a visit to Australia by delegates from Tsinghua University’s commercialisation arm, TusHoldings as part of a collaboration with the South Australian Health & Medical Research Institute, (SAHMRI) and the South Australian Government.
As an extension to this activity, Anthony established H+Lab Australia as a vehicle for further cross-border collaboration & exchange and has been hosting inbound & outbound delegations with TusHoldings’ investee companies, and the TusStar Global Innovation network. (www.tusstar.com)
TusStar provides ‘soft-landing’ market entry support for International businesses in Health, New Energy, Environment and Education, and VIP access into 100’s of Science Parks and Centres of Innovation across China, and now 10 Countries Internationally – including the new TusPark BioTech Hub within the Cambridge Science Park in the UK.
TusStar H+Lab China runs a $20M Venture Fund focussed on commercialising research & technology in Health & Wellbeing (幸福).
Anthony will introduce the Tsinghua commercialisation network and support services, along with sharing some insights into the opportunities for Australian businesses looking to commercialise in the Asia market.
Andrew Bowskill: MTPConnect
Andrew Bowskill is our Director of Stakeholder Engagement for Queensland, working from the MTPConnect office at the Translational Research Institute (TRI) in Woolloongabba, Brisbane. Andrew joins us from Medicines Australia, where he was Manager of Industry and Regulatory Policy, engaging with a broad cross section of stakeholders including consumer groups, companies, peak bodies and Commonwealth and State officials.
As well as his extensive networks, Andrew brings deep understanding of MTP industry and regulatory policy including R&D policy, intellectual property, trade agreements and biosimilars. Andrew has a Bachelor of Pharmacy from the University of Otago and has held a number of pharmacy roles in Queensland including Clinical Pharmacist, Adult Emergency and Medical Admissions and Planning Unit, Mater Pharmacy Services and Team Leader, Mater Private Hospital Pharmacy.
Chris Davis: Griffith University Institute for Gylcomics
Chris obtained an honours degree and PhD in synthetic medicinal chemistry from Griffith University on the Gold Coast. For 2 years he worked in a biotechnology start-up company developing anti-bacterial drug candidates he co-invented during his PhD. Following the trade sale of that company he worked for commercialisation company, Uniquest Pty Ltd., in Brisbane seeking venture capital investment to enable the development of new drug and vaccine discoveries, together with licensing of drug and vaccine technologies to biotechnology and pharmaceutical companies. In 2009 he returned to Griffith University as General Manager of the Institute for Glycomics where he leads a group of professionals dedicated to the strategic
and operational development of the Institute, covering domestic and international business strategy, technology commercialisation, fund raising across the philanthropic, government, industry and private sectors, and general Institute operations. The primary focus of the Institute is translating its drug, vaccine and diagnostic discoveries into social and economic benefit, locally and globally. Chris has devoted many years to understanding the Chinese pharma market and is experienced in packaging, pitching and negotiating commercial biomedical technology deals in China. Over the past 3 years Chris has closed 3 technology licence and co-development deals with Chinese Pharma companies. Outside of his employment with Griffith University, Chris is Chair of Ausbiotech Ltd, Queensland Branch.
Alan Robertson: ClearSky Genomics
Alan Robertson is the founder of ClearSKY Genomics; a startup that’s making it possible for more clinicians to utilise genetic testing, and more patients to understand what their DNA means. After seeing the disconnect between what was being done in research labs and what was being offered to patients in hospitals, Alan left his grown-up job to focus on ClearSKY. As a result, Alan takes every opportunity to make ClearSKY the best company it can be. One of those opportunities was BridgeTech and another one was PitchTech.
|Start Date:||25/11/2020 [add to calendar]|
|End Time:||1:00pm AEST|
|RSVP By:||Monday 16th of November 2020|